Heat Biologics Stock News

Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats Burel to support anthrax and RapidVax™ biodefense initiatives

Heat Biologics (HTBX) has presented favorable survival data at The American Association of Cancer Research of HS-110 in combination with checkpoint inhibitors for the treatment…

Heat Biologics (HTBX) said it plans to change its listing to the NYSE American stock exchange from from the Nasdaq Capital Market.Heat expects to begin trading on NYSE under its

DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modula

Elusys Therapeutics, which is being acquired by Heat Biologics <>, said it finalized a contract with the U.S

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023

Elusys Therapeutics Inc, the merger partner for Heat Biologics Inc HTBX, has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Depart

Heat Biologics Inc (NASDAQ: HTBX ) announced promising preclinical data regarding PTX-35 . The data has been accepted for publication in the American Journal of Transplantation. A single dose of the preclinical version of PTX-35 (mPTX-35) expanded regulatory T cells (Tregs) and significantly improved disease and graft survival outcomes. Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted Full story available on Benzinga.com

DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclinical data regarding PTX-35 has been accepted for publication in the American Journal of Transplantation and is available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.16940 . Key Findings : A single dose of the preclinical version of PTX-35 (mPTX-35), was able to expand regulatory T cells (Tregs) and significantly improve disease and graft survival outcomes. Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted with beta-cell islet allografts and treated with mPTX-35. Disease protection in preclinical models was correlated with a significant expansion of Tregs and protection of the allograft, resulting in euglycemia and a graft survival benefit. Long-term surviving grafts showed a marked increase in Treg infiltration which directly correlated with mPTX-35 agonist activity.

Heat Biologics Inc (NASDAQ: HTBX) announced promising preclinical data regarding PTX-35. The data has been accepted for publication in the American Journal of Transplantation.

Heat Biologics Inc (HTBX) shares closed 3.6% lower than its previous 52 week low, giving the company a market cap of $83M. The stock is currently down 38.4% year-to-date, down 41.1% over the past 12 months, and down 94.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 53.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -218.4% The company's stock price performance over the past 12 months lags the peer average by -225.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Heat Biologics Inc (NASDAQ: HTBX) will acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of Anthim (obiltoxaximab) Injection. The acquisition is expected to c

Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S.

State Street Corp increased its stake in Heat Biologics, Inc. (NASDAQ:HTBX) by 466.5% in the 2nd quarter, Holdings Channel reports. The fund owned 98,896 shares of the biopharmaceutical companys stock after buying an additional 81,440 shares during the quarter. State Street Corps holdings in Heat Biologics were worth $666,000 at the end of the most []